Clinical practice guideline adherence in oncology: A qualitative study of insights from clinicians in Australia.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
21
03
2022
accepted:
30
11
2022
entrez:
16
12
2022
pubmed:
17
12
2022
medline:
21
12
2022
Statut:
epublish
Résumé
The burden of cancer is large in Australia, and rates of cancer Clinical Practice Guideline (CPG) adherence is suboptimal across various cancers. The objective of this study is to characterise clinician-perceived barriers and facilitators to cancer CPG adherence in Australia. Semi-structured interviews were conducted to collect data from 33 oncology-focused clinicians (surgeons, radiation oncologists, medical oncologists and haematologists). Clinicians were recruited in 2019 and 2020 through purposive and snowball sampling from 7 hospitals across Sydney, Australia, and interviewed either face-to-face in hospitals or by phone. Audio recordings were transcribed verbatim, and qualitative thematic analysis of the interview data was undertaken. Human research ethics committee approval and governance approval was granted (2019/ETH11722, #52019568810127). Five broad themes and subthemes of key barriers and facilitators to cancer treatment CPG adherence were identified: Theme 1: CPG content; Theme 2: Individual clinician and patient factors; Theme 3: Access to, awareness of and availability of CPGs; Theme 4: Organisational and cultural factors; and Theme 5: Development and implementation factors. The most frequently reported barriers to adherence were CPGs not catering for patient complexities, being slow to be updated, patient treatment preferences, geographical challenges for patients who travel large distances to access cancer services and limited funding of CPG recommended drugs. The most frequently reported facilitators to adherence were easy accessibility, peer review, multidisciplinary engagement or MDT attendance, and transparent CPG development by trusted, multidisciplinary experts. CPGs provide a reassuring framework for clinicians to check their treatment plans against. Clinicians want cancer CPGs to be frequently updated utilising a wiki-like process, and easily accessible online via a comprehensive database, coordinated by a well-trusted development body. Future implementation strategies of cancer CPGs in Australia should be tailored to consider these context-specific barriers and facilitators, taking into account both the content of CPGs and the communication of that content. The establishment of a centralised, comprehensive, online database, with living wiki-style cancer CPGs, coordinated by a well-funded development body, along with incorporation of recommendations into point-of-care decision support would potentially address many of the issues identified.
Sections du résumé
BACKGROUND
The burden of cancer is large in Australia, and rates of cancer Clinical Practice Guideline (CPG) adherence is suboptimal across various cancers.
METHODS
The objective of this study is to characterise clinician-perceived barriers and facilitators to cancer CPG adherence in Australia. Semi-structured interviews were conducted to collect data from 33 oncology-focused clinicians (surgeons, radiation oncologists, medical oncologists and haematologists). Clinicians were recruited in 2019 and 2020 through purposive and snowball sampling from 7 hospitals across Sydney, Australia, and interviewed either face-to-face in hospitals or by phone. Audio recordings were transcribed verbatim, and qualitative thematic analysis of the interview data was undertaken. Human research ethics committee approval and governance approval was granted (2019/ETH11722, #52019568810127).
RESULTS
Five broad themes and subthemes of key barriers and facilitators to cancer treatment CPG adherence were identified: Theme 1: CPG content; Theme 2: Individual clinician and patient factors; Theme 3: Access to, awareness of and availability of CPGs; Theme 4: Organisational and cultural factors; and Theme 5: Development and implementation factors. The most frequently reported barriers to adherence were CPGs not catering for patient complexities, being slow to be updated, patient treatment preferences, geographical challenges for patients who travel large distances to access cancer services and limited funding of CPG recommended drugs. The most frequently reported facilitators to adherence were easy accessibility, peer review, multidisciplinary engagement or MDT attendance, and transparent CPG development by trusted, multidisciplinary experts. CPGs provide a reassuring framework for clinicians to check their treatment plans against. Clinicians want cancer CPGs to be frequently updated utilising a wiki-like process, and easily accessible online via a comprehensive database, coordinated by a well-trusted development body.
CONCLUSION
Future implementation strategies of cancer CPGs in Australia should be tailored to consider these context-specific barriers and facilitators, taking into account both the content of CPGs and the communication of that content. The establishment of a centralised, comprehensive, online database, with living wiki-style cancer CPGs, coordinated by a well-funded development body, along with incorporation of recommendations into point-of-care decision support would potentially address many of the issues identified.
Identifiants
pubmed: 36525435
doi: 10.1371/journal.pone.0279116
pii: PONE-D-22-08374
pmc: PMC9757567
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0279116Informations de copyright
Copyright: © 2022 Bierbaum et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Cochrane Database Syst Rev. 2019 Jun 24;6:CD000125
pubmed: 31232458
BMJ Open. 2016 Jul 29;6(7):e012467
pubmed: 27473955
JAMA. 2009 Feb 25;301(8):868-9
pubmed: 19244197
Radiother Oncol. 2015 Nov;117(2):386-9
pubmed: 26243679
J Med Imaging Radiat Oncol. 2020 Feb;64(1):134-143
pubmed: 31793211
Cochrane Database Syst Rev. 2009 Apr 15;(2):CD003030
pubmed: 19370580
J Thorac Oncol. 2010 Jul;5(7):1025-32
pubmed: 20453689
Asia Pac J Clin Oncol. 2017 Oct;13(5):e373-e380
pubmed: 27726297
Rural Remote Health. 2017 Dec;17(4):4199
pubmed: 29262688
J Eval Clin Pract. 2018 Feb;24(1):135-144
pubmed: 28474459
Cochrane Database Syst Rev. 2007 Oct 17;(4):CD000409
pubmed: 17943742
J Clin Epidemiol. 2015 May;68(5):498-509
pubmed: 25684154
Asia Pac J Clin Oncol. 2021 Apr;17(2):e77-e86
pubmed: 32298539
J Geriatr Oncol. 2021 Jul;12(6):930-936
pubmed: 34119452
J Thorac Oncol. 2008 Aug;3(8):871-9
pubmed: 18670305
J Eval Clin Pract. 2021 Feb;27(1):175-192
pubmed: 32342613
BMC Cancer. 2015 Jul 11;15:515
pubmed: 26163015
Cancer Epidemiol Biomarkers Prev. 2020 Dec;29(12):2669-2679
pubmed: 32948632
Cardiol Rev. 2019 Mar/Apr;27(2):80-86
pubmed: 29634492
J Gen Intern Med. 2007 Mar;22(3):289-96
pubmed: 17356957
Med J Aust. 2007 Mar 19;186(6):292-5
pubmed: 17371209
Breast. 2010 Oct;19(5):396-401
pubmed: 20452216
Ann Surg Oncol. 2017 Aug;24(8):2080-2088
pubmed: 28547563
JAMA Netw Open. 2020 Mar 2;3(3):e200841
pubmed: 32167566
Asia Pac J Clin Oncol. 2017 Oct;13(5):e224-e231
pubmed: 26997361
Intern Med J. 2020 Jan;50(1):30-37
pubmed: 31943616
Trials. 2015 Nov 03;16:495
pubmed: 26530985
Breast. 2012 Aug;21(4):570-7
pubmed: 22425535
PLoS Med. 2006 Jun;3(6):e134
pubmed: 16737346
J Med Imaging Radiat Oncol. 2018 Apr;62(2):270-275
pubmed: 29080296
Crit Care Med. 2010 Aug;38(8 Suppl):S282-91
pubmed: 20647785
Cancer. 2018 Sep 15;124(18):3656-3667
pubmed: 30216477
Breast. 2010 Oct;19(5):345-9
pubmed: 20223666
J Oncol Pract. 2014 May;10(3):e146-9
pubmed: 24667293
Mol Oncol. 2020 Jul;14(7):1442-1460
pubmed: 32198967
BMJ Open. 2020 Mar 23;10(3):e035448
pubmed: 32205377
Tech Coloproctol. 2010 Sep;14(3):229-35
pubmed: 20632061
J Clin Oncol. 2017 Jun 1;35(16):1845-1854
pubmed: 28358653
Int J Qual Health Care. 2015 Oct;27(5):418-20
pubmed: 26294709
Cancer. 2005 Sep 15;104(6):1129-37
pubmed: 16080176
Eur J Cancer. 2007 Apr;43(6):1002-10
pubmed: 17329094
Implement Sci. 2006 Apr 28;1:9
pubmed: 16722539
Gastroenterol Res Pract. 2015;2015:753480
pubmed: 25883645
Int J Qual Health Care. 2007 Dec;19(6):349-57
pubmed: 17872937
J Med Imaging Radiat Oncol. 2015 Aug;59(4):535-541
pubmed: 26076378
J Clin Oncol. 2012 Mar 20;30(9):972-9
pubmed: 22355049
Med Educ. 2016 May;50(5):590-1
pubmed: 27072480
Implement Sci. 2012 May 31;7:50
pubmed: 22651257
BMC Cancer. 2019 Jun 11;19(1):570
pubmed: 31185937
Clin Oncol (R Coll Radiol). 2016 Oct;28(10):639-47
pubmed: 27211609
JAMA. 2013 Dec 18;310(23):2501-2
pubmed: 24310916
CMAJ. 2010 Feb 9;182(2):E78-84
pubmed: 19969563
J Eval Clin Pract. 2014 Aug;20(4):467-77
pubmed: 24851796
Breast. 2012 Aug;21(4):562-9
pubmed: 22297168
Cochrane Database Syst Rev. 2016 Aug 22;(8):CD010669
pubmed: 27546228
Cochrane Database Syst Rev. 2009 Jul 08;(3):CD001096
pubmed: 19588323
BJU Int. 2014 Nov;114 Suppl 1:50-4
pubmed: 25070295
Implement Sci. 2012 Jul 04;7:62
pubmed: 22762242
Clin Oncol (R Coll Radiol). 2012 Feb;24(1):e9-17
pubmed: 21802914
Radiother Oncol. 2018 Feb;126(2):191-197
pubmed: 29229506
Lancet. 2017 Jul 22;390(10092):415-423
pubmed: 28215660
Cancer Epidemiol. 2015 Aug;39(4):600-11
pubmed: 26004990
Pract Radiat Oncol. 2017 Sep - Oct;7(5):332-338
pubmed: 28284760
Aust J Rural Health. 2012 Oct;20(5):259-64
pubmed: 22998200
JMIR Med Educ. 2016 Nov 30;2(2):e16
pubmed: 27903488
Implement Sci. 2020 May 27;15(1):39
pubmed: 32460797
Implement Sci. 2018 May 29;13(1):72
pubmed: 29843737
EBioMedicine. 2019 Aug;46:27-29
pubmed: 31303500
Implement Sci. 2020 Jun 3;15(1):41
pubmed: 32493348
JAMA. 2018 Mar 20;319(11):1113-1124
pubmed: 29558552
Cochrane Database Syst Rev. 2012 Jun 13;(6):CD000259
pubmed: 22696318
Med J Aust. 2021 Apr;214(6):271-278
pubmed: 33665811
Acad Med. 2014 Sep;89(9):1245-51
pubmed: 24979285
Cochrane Database Syst Rev. 2020 Jul 31;8:CD004398
pubmed: 32748975
Med J Aust. 2014 Oct 20;201(8):445-6
pubmed: 25332023
Sarcoma. 2015;2015:614179
pubmed: 25784832
Oncologist. 2014 Oct;19(10):1069-75
pubmed: 25170014
Health Serv Res. 2013 Dec;48(6 Pt 2):2134-56
pubmed: 24279835
J Med Imaging Radiat Oncol. 2020 Apr;64(2):261-270
pubmed: 32037663
Asia Pac J Clin Oncol. 2016 Mar;12(1):52-60
pubmed: 26481765
BMC Fam Pract. 2013 Aug 26;14:124
pubmed: 23972115
Ann Fam Med. 2011 Jan-Feb;9(1):22-30
pubmed: 21242557
BMJ Qual Saf. 2011 Apr;20 Suppl 1:i83-6
pubmed: 21450780
BMJ. 2001 May 5;322(7294):1115-7
pubmed: 11337448